Mesothelioma is a malignant tumour of pleura and other serosal tissues. it arises many years after asbestos exposure. There is currently no highly effective therapy and the median survival is approximately 10-12 months from diagnosis. Most patients cannot be treated surgically due to the advanced stage of the disease at diagnosis or are unfit for radical surgery. New antifolate drugs (pemetrexed or raltitrexed) in combination with platinum are associated with longer median survival than platinum alone, an increase which averages about three months. radiation therapy is limited by its toxicity to the underlying lung, but newer field and dose planning methods are under investigation. Mesothelioma presents major challenges for the palliative management of dyspnoea, pain, and cancer cachexia syndrome.
introduction
Mesothelioma is an aggressive tumour of serosal surfaces, most commonly the pleura, associated with exposure to asbestos often many years previously. In Australian men the age standardised incidence of mesothelioma rose from 2. 
Surgical treatment
The role of surgery alone in mesothelioma is debatable. nonrandomised studies of radical trimodality treatment (extrapleural pneumonectomy, chemotherapy and radiotherapy) report median survival rates of 9.4 to 27.5 months. Extended survival is more likely in those with complete resections, epithelial histology, and without involvement of extrapleural nodes. This management approach may be suitable for highly selected patients with good functional status who have Stage 1 or 2 epithelioid tumour subtypes and can be treated in a centre with specific surgical expertise, but it is generally unsuitable for the majority of patients.
Key trials underpinning current 'standard' chemotherapy
Establishing a 'standard' active chemotherapy for mesothelioma has been difficult. There are few randomised trials, they involve small numbers of patients and the response to treatment is difficult to measure. There is difficulty comparing trial results 12 and folic acid reduced the haematologic toxicity of pemetrexed/cisplatin including rates of febrile neutropenia and infection, and non-haematological toxicity including nausea and vomiting without reducing the efficacy of the combination. 3 Superior pain, dyspnoea, and fatigue scores, as well as stabilisation of global quality of life and activity level scores were subsequently reported for patients on the combination arm of this study. A similarly designed study of platinum with raltitrexed (a specific inhibitor of thymidilate synthase) also showed a similar survival advantage for the combination compared with cisplatin alone, as well as no deterioration in health related quality of life over time in either arm. 4 Although there is no published randomised study of single drug platinum versus no chemotherapy, it is assumed that platinum alone is either active or at least not detrimental. These studies showing a survival benefit and improved quality of life for patients treated with antifolates plus platinum over platinum alone, underpin the Australian approval of pemetrexed in combination with platinum as first-line chemotherapy for mesothelioma.
Antifolate combinations
Further experience with antifolates in mesothelioma was gained in expanded access programs in the USA and Europe. These non-randomised studies report that median survival for patients given platinum with pemetrexed is longer than with pemetrexed alone in both first-and second-line settings. However, there is a possible bias that fitter patients may have been selected for combination chemotherapy rather than pemetrexed alone. 5 
Combination regimen
For patients with good performance status and adequate end-organ function, the standard treatment in Australia is pemetrexed 500 mg/m 2 as a 10-minute intravenous infusion followed by cisplatin 75 mg/m 2 over two hours on day one of 21-day cycles. Pharmaceutical costs are approximately $19 000 for six cycles of treatment. Patients must take folic acid 350-1000 microgram daily (usually 500 microgram) and be given vitamin B 12 1000 microgram intramuscularly seven days before the start of treatment repeated nine-weekly during treatment to reduce haematological and non-haematological toxicity. Dexamethasone is given for three days starting the day before pemetrexed therapy to reduce the risk of skin rash.
A single small randomised study of chemotherapy given immediately after diagnosis or delayed until symptoms progressed showed that the duration of controlled symptoms and survival were longer in patients receiving immediate treatment. 6 Although the difference of four months in median survival was not statistically significant, it suggests that there is no advantage in delaying treatment.
There is a lack of data concerning optimal duration of treatmentpatients in the single-blind study received 1-12 cycles, with a median of six. 3 Treatment is usually given for a total of six cycles or ceased earlier if the patient develops progressive disease or unacceptable toxicity. Carboplatin may be substituted for cisplatin in patients with mild to moderately impaired renal function (response rates were similar to the cisplatin-based combination). 7 The International Expanded Access program also included carboplatin. 8 Platinum drugs and pemetrexed are contraindicated in severe renal insufficiency.
Second-line and maintenance treatment
To date there is one randomised study of treatment after failure of first-line chemotherapy. Second-line treatment with pemetrexed was associated with prolonged progression-free survival compared with best supportive care (median 3.6 months vs 1.5 months), 9 
Clinical trials of targeted treatments
The presence of growth factor receptors in mesothelioma has prompted research into targeted therapies.
Epithelial growth factor receptor tyrosine kinase inhibitors
Epithelial growth factor receptor (EGFR) is often overexpressed in mesothelioma. However, phase II trials of the EGFR tyrosine kinase inhibitors erlotinib and gefitinib have not reported objective responses.
Vascular endothelial growth factor inhibitors
Vascular endothelial growth factor (VEGF) is an autocrine growth factor which induces new blood vessel formation. High concentrations of VEGF are associated with a poorer prognosis in mesothelioma. In phase II trials the antiangiogenic drugs bevacizumab, sorafenib and sunitinib have been relatively well tolerated, but have produced generally low response rates. 10 There was no advantage when bevacizumab was added to cisplatin and gemcitabine. 11 A randomised phase II/III trial (IFCT-GFPC-0701) of cisplatin and pemetrexed with or without bevacizumab as first-line treatment reported superior outcomes for the bevacizumab arm 12 and so recruitment will continue to complete the phase III trial.
Histone deacetylase inhibitors
Histone deacetylase inhibitors, such as sodium valproate, activate transcription of genes involved in apoptosis, cell proliferation and angiogenesis. Trials of sodium valproate in patients with progressive disease found some biological activity. numerous newer drugs in this class are in testing including a phase III trial of vorinostat.
Ranpirnase
Ranpirnase is a ribonuclease which disrupts protein translation.
It showed disease modifying activity by stabilising progressive disease, but a phase III trial of adding ranpirnase to adriamycin showed no overall survival advantage.
Proteasome inhibitors
The transcription factor nF-κΒ regulates proteins associated with evasion of apoptosis. Proteasome inhibitors interfere with degradation of inhibitor-κB, and so restore apoptosis. Two phase II studies of bortezomib are in progress.
Mammalian target of rapamycin inhibitors
Loss of a tumour suppressor in mesothelioma activates the mammalian target of rapamycin (mToR), a serine threonine kinase. This enzyme is highly expressed in mesothelioma, providing a rationale for evaluation of mToR inhibitors such as rapamycin itself (sirolimus) and analogues temsirolimus and everolimus (currently in phase II trial).
Imatinib
Signalling by platelet derived growth factor receptor promotes mesothelioma growth. Imatinib mesylate, an inhibitor of the enzyme associated with this receptor, was ineffective as a single drug, but increased tumour xenograft uptake of other anticancer drugs by its effect on tumour endothelium. There is now a phase II trial of gemcitabine plus imatinib. 
Vascular disrupting drugs

Thalidomide
Thalidomide has anti-angiogenesis and other complex antitumour activity. There is a collaborative Dutch and Australian trial which is studying pemetrexed-based chemotherapy with or without maintenance thalidomide.
Novel first-line drugs
Mesothelin is a cytoplasmic membrane glycoprotein involved in cell adhesion and is proposed as a diagnostic and treatment response biomarker for mesothelioma. An anti-mesothelin monoclonal antibody Morab-009 (amatuximab) is in phase II trial. Also being studied are an anti-mesothelin antibody conjugated with pseudomonas exotoxin A, and a mesothelin vaccine designed to elicit an antibody dependent cytotoxicity response against mesothelin expressing tumour cells.
palliative management
Effective palliative management of mesothelioma often requires multiple interventions to alleviate symptoms of dyspnoea due to recurrent pleural effusion or lung encasement, pain due to parietal pleural irritation or intercostal nerve compression or invasion, and anorexia cachexia syndrome. An excellent review of palliative care for mesothelioma 13 
Conclusion
There is no cure for malignant mesothelioma. Radical treatments remain unproven by randomised controlled clinical trial, and only a minority of patients are eligible for such therapy. Although platinum with antifolate chemotherapy is effective in prolonging survival and improves quality of life, it is not without toxicity and is not curative. Effective palliation for symptomatic disease requires an active pre-emptive approach.
Vigorous research efforts are still required to discover effective treatment or secondary prevention strategies for a disease with an increasing worldwide incidence.
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